Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Patented Medicines Regulations (SOR/94-688)

Regulations are current to 2024-10-30 and last amended on 2022-07-01. Previous Versions

Patented Medicines Regulations

SOR/94-688

PATENT ACT

Registration 1994-11-07

Patented Medicines Regulations

P.C. 1994-1819  1994-11-01

His Excellency the Governor General in Council, on the recommendation of the Minister of National Health and Welfare, pursuant to section 101Footnote * of the Patent Act, is pleased hereby to revoke the Patented Medicines Regulations, made by Order in Council P.C. 1988-2013 of September 15, 1988Footnote **, and to make the annexed Regulations specifying the information to be provided relating to patented medicines and patentees’ revenues and research and development expenditures, in substitution therefor.

1 [Repealed, SOR/2008-70, s. 2]

Previous Version

Interpretation

[
  • SOR/98-105, s. 1(F)
]

2 The definitions in this section apply in these Regulations.

Act

Act means the Patent Act. (Loi)

notice of compliance

notice of compliance means a notice issued under section C.08.004 or C.08.004.01 of the Food and Drug Regulations. (avis de conformité)

  • SOR/98-105, s. 1
  • SOR/2013-122, s. 24
Previous Version

Information Respecting the Identity and Price of Medicines

  • 3 (1) For the purposes of paragraphs 80(1)(a) and (2)(a) of the Act, information identifying the medicine shall be accompanied by the product monograph for the medicine or, if a notice of compliance has not been issued in respect of the medicine, by information similar to that contained in a product monograph, and shall indicate

    • (a) the name and address of the rights holder or former rights holder and their address for correspondence in Canada;

    • (b) whether the reporting rights holder referred to in paragraph (a) is a patent holder, a holder of a certificate of supplementary protection, a person holding a licence other than a licence continued by subsection 11(1) of the Patent Act Amendment Act, 1992, or any other person referred to in the definition rights holder in subsection 79(1) of the Act;

    • (c) the generic name and brand name of the medicine;

    • (d) whether the medicine is for human or veterinary use;

    • (e) the therapeutic use of the medicine approved by the Minister of Health;

    • (f) the date on which the first notice of compliance was issued to the rights holder or former rights holder in respect of the medicine;

    • (g) the drug identification number assigned to each strength and dosage form of the medicine under the Food and Drug Regulations;

    • (h) the patent number of each invention of the patentee or former patentee pertaining to the medicine, the date on which each patent was granted and the date on which each patent will expire; and

    • (i) for each certificate of supplementary protection that has been issued in respect of each invention pertaining to the medicine of the rights holder or former rights holder:

      • (i) the number of the certificate of supplementary protection,

      • (ii) the date on which the certificate takes effect and the date on which it expires, and

      • (iii) the number of the patent set out in the application for the certificate of supplementary protection.

  • (2) The information required under subsection (1) shall be provided if

    • (a) a notice of compliance has been issued in respect of the medicine; or

    • (b) the medicine is being offered for sale in Canada.

  • (3) The information referred to in subsection (1) shall be provided no later than the earlier of

    • (a) seven days after the day on which the first notice of compliance is issued in respect of the medicine; and

    • (b) seven days after the day on which the medicine is first offered for sale in Canada.

  • (3.1) Despite subsection (3), in each of the following cases, the information referred to in subsection (1) shall be provided within 30 days after the day on which the Board sends a request for the rights holder to provide that information:

    • (a) the medicine is not a prescription drug as defined in section A.01.010 of the Food and Drug Regulations and is not a drug described in Schedule D to the Food and Drugs Act;

    • (b) the medicine contains a controlled substance as defined in subsection 2(1) of the Controlled Drugs and Substances Act, the sale or provision of which does not require a prescription under that Act;

    • (c) a notice of compliance has been issued in respect of the medicine on the basis of information and material contained in a submission filed under section C.08.002.1 of the Food and Drug Regulations;

    • (d) the medicine is for veterinary use.

  • (4) The information referred to in subsection (1) shall be up to date and any modification of that information shall be reported within 30 days after the modification.

Previous Version

  • 4 (1) For the purposes of paragraphs 80(1)(b) and (2)(b) of the Act, information identifying the medicine and concerning the price of the medicine shall indicate

    • (a) the identity of the rights holder or former rights holder;

    • (b) the generic name and brand name of the medicine;

    • (c) the date on which the medicine is first sold in Canada;

    • (d) the day or period, referred to in subsection (2) or (3), to which the information pertains;

    • (e) the drug identification number assigned under the Food and Drug Regulations in respect of the medicine or, if no drug identification number has been assigned, any other identification number assigned in respect of each dosage form and strength of the medicine of the rights holder or former rights holder; and

    • (f) in respect of the day or period referred to in paragraph (d),

      • (i) the quantity of the medicine sold in final dosage form and either the average price per package or the net revenue from sales in respect of each dosage form, strength and package size in which the medicine was sold by the rights holder or former rights holder to each class of customer in each province and territory,

      • (ii) the publicly available ex-factory price for each dosage form, strength and package size in which the medicine was sold by the rights holder or former rights holder to each class of customer in each province and territory, and

      • (iii) if the medicine is being sold in one or more of the countries set out in the schedule, the publicly available ex-factory price for each dosage form, strength and package size in which the medicine was sold to each class of customer in each of those countries.

    • (g) [Repealed, SOR/2008-70, s. 4]

  • (2) The information referred to in subsection (1) shall be provided to the Board

    • (a) for the day on which the medicine is first sold in Canada, within 30 days after that day; and

    • (b) for each six-month period beginning on January 1 and July 1 in a year, within 30 days after the end of the period.

  • (3) Despite subsection (2), in each of the following cases, the information referred to in subsection (1), for each six-month period beginning on January 1 and July 1 of each year, shall be provided within 30 days after the day on which the Board sends a request for the rights holder to provide that information and, during the two years following the request, within 30 days after the end of each six-month period:

    • (a) the medicine is not a prescription drug as defined in section A.01.010 of the Food and Drug Regulations and is not a drug described in Schedule D to the Food and Drugs Act;

    • (b) the medicine contains a controlled substance as defined in subsection 2(1) of the Controlled Drugs and Substances Act, the sale or provision of which does not require a prescription under that Act;

    • (c) a notice of compliance has been issued in respect of the medicine on the basis of information and material contained in a submission filed under section C.08.002.1 of the Food and Drug Regulations;

    • (d) the medicine is for veterinary use.

  • (4) For the purposes of subparagraph (1)(f)(i),

    • (a) in calculating the average price per package of medicine, the actual price after any reduction given as a promotion or in the form of rebates, discounts, refunds, free goods, free services, gifts or any other benefit of a like nature and after the deduction of the federal sales tax shall be used; and

    • (b) in calculating the net revenue from sales of each dosage form, strength and package size in which the medicine was sold in final dosage form, the actual revenue after any reduction in the form of rebates, discounts, refunds, free goods, free services, gifts or any other benefit of a like nature and after the deduction of federal sales taxes shall be used.

  • (5) Subject to subsection (6), this section does not apply to medicine sold by a rights holder or former rights holder to a person with whom they do not deal at arm’s length or to another rights holder or former rights holder.

  • (6) If the rights holder or former rights holder sells the medicine to a person with whom they do not deal at arm’s length and who is not required to provide information under paragraph 80(1)(a) or (2)(a) of the Act, the rights holder or former rights holder shall provide the information required under paragraph (1)(f) in respect of any resale of the medicine by the person.

  • (7) For the purposes of subparagraph (1)(f)(iii), the price at which a medicine was sold in a country other than Canada shall be expressed in the currency of that country.

  • (8) For the purposes of this section, the Income Tax Act, as that Act read on December 1, 1987, applies, with any modifications that the circumstances require, in determining whether a rights holder or former rights holder is dealing at arm’s length with another person.

  • (9) For the purposes of this section, publicly available ex-factory price includes any price of a patented medicine or medicine protected by a certificate of supplementary protection that is agreed on by the rights holder or former rights holder and the appropriate regulatory authority of the country in which the medicine is sold by the rights holder.

  • (10) [Repealed, SOR/2008-70, s. 4]

Previous Version

Revenues and Research and Development Expenditures

  • 5 (1) For the purposes of subsection 88(1) of the Act, information concerning the identity of any licensee in Canada of the rights holder and the revenues and research and development expenditures of the rights holder shall indicate

    • (a) the name and address of the rights holder and their address for correspondence in Canada;

    • (b) the name and address of all licensees in Canada of the rights holder;

    • (c) the total gross revenues from all sales in Canada during the year by the rights holder of medicine for human and veterinary use and the total revenues received from all licensees from the sale in Canada of medicine for human and veterinary use; and

    • (d) a summary of all expenditures made during the year by the rights holder towards the cost of research and development relating to medicine for human or veterinary use carried out in Canada by or on behalf of the rights holder, including

      • (i) a description of the type of research and development and the name of the person or entity that carried out the research and development,

      • (ii) the expenditures of the rights holder or the person or entity that carried out the research and development, in respect of each type of research and development, and

      • (iii) the name of the province in which the research and development was carried out and the expenditures in that province by the rights holder or the person or entity.

  • (2) The information referred to in subsection (1) shall be provided for each calendar year and shall be submitted within 60 days after the end of each calendar year.

  • (3) The total gross revenues referred to in paragraph (1)(c) shall comprise revenues from sales of medicine

    • (a) for which a drug identification number has been issued under the Food and Drug Regulations or which has been approved for sale to qualified investigators under those Regulations;

    • (b) that is used in the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state or the symptoms thereof or in the modification of organic functions in humans or animals; and

    • (c) the sale of which is promoted by any means to physicians, dentists, veterinarians, hospitals, drug retailers or wholesalers or manufacturers of ethical pharmaceutical products.

  • (4) For the purposes of paragraph (1)(d), the rights holder shall specify

    • (a) the total capital expenditures on buildings and the annual depreciation of the buildings which depreciation shall be calculated at an annual rate of four per cent for a maximum of 25 years;

    • (b) the total capital expenditures on equipment; and

    • (c) the source and amount of the funds for expenditures made by the rights holder towards the cost of research and development.

Previous Version

Table of Contents

 

Date modified: